INTERNATIONAL BIOTECHNOLOGY TRUST PLC (the Company)
Portfolio Update as at 30 June 2018
Net Assets |
£242m |
Net Assets per share |
646p |
Share price |
610p |
Total value of unquoted investments |
£26m |
Total number of portfolio companies |
75 |
Dividend |
4% of NAV per annum |
Top Ten Quoted Investments
Company Name |
% NAV |
Neurocrine |
5.0 |
Celgene |
4.7 |
Vertex |
4.4 |
Morphosys |
4.3 |
Illumina |
3.9 |
Array |
3.6 |
Genmab |
3.6 |
Regeneron |
3.4 |
Biogen |
3.3 |
Alexion |
3.2 |
|
----------- |
Total |
39.4 |
Geographical Allocation |
% NAV |
US & Canada |
85 |
Europe |
15 |
|
----------- |
Total |
100 |
Quoted/Unquoted Allocation |
% NAV |
Quoted |
89 |
Unquoted |
11 |
|
----------- |
Total |
100 |
NAV % Market Cap |
% NAV |
Large Cap >USD10BN |
34 |
Mid Cap =USD1-10BN |
42 |
Small Cap <USD1BN |
24 |
|
----------- |
Total |
100 |
NAV % by Therapeutic Areas |
% NAV |
Oncology |
44 |
CNS |
14 |
Rare diseases |
13 |
Ophthalmology |
6 |
Inflammation |
5 |
Infectious Diseases |
3 |
Metabolic |
2 |
Medtech |
2 |
Other |
11 |
|
----------- |
Total |
100 |
BNP Paribas Secretarial Services Limited
Company Secretary
18 JULY 2018